Jointown Pharmaceutical Group Co., Ltd.

Founded in 1999 and headquartered in Wuhan, China, Jointown Pharmaceutical Group (referred to as "Jointown," stock code: 600998) has evolved into a prominent Chinese listed conglomerate. Our core operations encompass the distribution of pharmaceuticals, traditional Chinese medicine, medical devices, and active pharmaceutical ingredients (APIs). We are dedicated to delivering added-value information and logistics services to a wide spectrum of clients, including pharmaceutical manufacturers, medical institutions, wholesale enterprises, and retail pharmacies.

Jointown prides itself on its robust domestic sales network within China's medical health industry, setting us apart as a leader in the field. Over the years, our commitment to excellence has consistently placed us at the forefront of the Chinese pharmaceutical sector. We boast the title of China's premier privately-owned pharmaceutical enterprise and ranked 158th among China's top 500 companies by Fortune magazine in 2014.

As of September 30, 2014, Jointown's financial standing includes a registered capital of 1.643 billion RMB, total assets amounting to 22.188 billion RMB, and an annual sales revenue of 30.628 billion RMB. Our dynamic team comprises nearly 10,000 professionals, 100 subsidiary branches, and 816 directly-operated and franchised pharmacies.

In terms of international outreach, our Pharmaceutical Industry Division is not only an exporter of APIs produced by our subsidiaries but also a purveyor of high-quality APIs from other esteemed Chinese manufacturers. Additionally, we import top-tier APIs from leading global pharmaceutical companies to satisfy the diverse needs of our clientele in China.

Our business philosophy is anchored in the principles of cost-efficiency and high performance, with a steadfast focus on providing economical services to the pharmaceutical and healthcare sectors. We are eager to establish ourselves as your trusted ally in fostering global human health.